Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma

The discovery of BRAF mutations in the majority of patients with metastatic melanoma combined with the identification of highly selective BRAF inhibitors have revolutionized the treatment of patients with metastatic melanoma. The first highly specific BRAF inhibitor, vemurafenib, began clinical test...

Descripción completa

Detalles Bibliográficos
Autores principales: Swaika, Abhisek, Crozier, Jennifer A, Joseph, Richard W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064951/
https://www.ncbi.nlm.nih.gov/pubmed/24966667
http://dx.doi.org/10.2147/DDDT.S31143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064951/
https://www.ncbi.nlm.nih.gov/pubmed/24966667
http://dx.doi.org/10.2147/DDDT.S31143

Ejemplares similares